Bicycle Therapeutics Duravelo-2 Phase 2 Detailed Data (May 22): 65% ORR (17/26) and 58% BICR-Confirmed ORR (15/26) at 27-Week Cutoff for Zelenectide Pevedotin + Pembrolizumab in 1L Urothelial Cancer
Bicycle Therapeutics' formal post-ASCO 2026 press release Friday morning specified the headline Phase 2 numbers from yesterday's abstract release. In the Duravelo-2 combination cohort, the optimal zelenectide dose plus pembrolizumab 200 mg every three weeks produced 65% ORR (17/26 evaluable patients) regardless of confirmation, with 58% BICR-confirmed ORR (15/26) at the 27-week cutoff in previously untreated locally advanced or metastatic urothelial cancer. An additional confirmed BICR response observed after the cutoff would bring the rate to 62%. The trial tested two dose schedules: 5 mg/m² weekly and 6 mg/m² two-weeks-on-one-week-off; the optimal dose moves forward. Treatment retention was high and dose-limiting adverse events limited. The 65% ORR is similar to the 65% (13/20) seen with the same combination in untreated cisplatin-ineligible patients in the earlier Duravelo-1 trial, though comparisons across trials are limited.